Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 1
Submit an article Journal homepage
143
Views
0
CrossRef citations to date
0
Altmetric
Review

Aggrenox® versus other pharmacotherapy in preventing recurrent stroke

Andrea R Redman Department of Clinical and Administrative Sciences, 3001 Mercer University Drive, Atlanta, GA 30341, USA. [email protected]
&
Gina J Ryan Department of Clinical and Administrative Sciences, 3001 Mercer University Drive, Atlanta, GA 30341, USA. [email protected]
Pages 117-123 | Published online: 02 Mar 2005

Bibliography

  • AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics - 2003 update. American Heart Association, Dallas, TX, USA (2002):15–17.
  • LOVE BB, BILLER J: Neurovascular System. In: Textbook of Clinical Neurology Goetz CG, Pappert EJ (Eds), WB Saunders, Philadephia, USA (1999):373.
  • ALBERS GW, CAPLAN LR, EASTON JD et al.: Transient ischemic attack - proposal for a new definition. N Engl. I Med. (2002) 347:1713–1716.
  • BRADBERRY JC, FAGAN SC: Stroke. In: Pharmacotherapy: a pathophysiologic approach. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds), McGraw-Hill, New York, USA (2002):375–394.
  • WOLF PA, D'AGOSTINO RB, BELANGER AJ, KANNEL WB: Probability of stroke: a risk profile from the Framingham Study. Stroke (1991) 22:312–318.
  • KNUIMAN MW, HIEN TVV: Risk factors for stroke mortality in men and women: the Busselton Study. Cardiovasc. Rick. (1996) 3:447–452.
  • ALBERS GW, AMARENCO P, EASTON JD, SAC CO RL, TEAL P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest (2001) 119:300S–320S.
  • ALBERS GW, HART RG, LUTSEP HL, NEWELL DW, SACCO RL: AHA Scientific Statement: supplement to the guidelines for the management of transient ischemic attacks. Stroke (1999) 30:2502–2511.
  • THEROUX P, BLANCHARD A: Antiplatelet therapy in cardiovascular disease. Cardiol Gin. Ann. Drug The]: (1997) 1:191–205.
  • ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. (1994) 308:81–106.
  • THE SALT COLLABORATIVE GROUP: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet (1991) 338:1345–1349.
  • FARRELL B, GODWIN J, RICHARDS S, WARLOW C: The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. Neurol Neurosurg. Psychiatry (1991) 54:1044–1054.
  • THE DUTCH TIA TRIAL STUDY GROUP: A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl. I Med. (1991) 325:1261–1266.
  • HAMBLETON J, O'REILLY RA: Drugs used in disorders of coagulation. In: Basic and clinical pharmacology Katzung BG (Ed.), McGraw-Hill, New York, USA (2001):564–580.
  • COLMAN RW, MARDER VJ, SALZMAN EW, HIRSH J: Overview of hemostasis. In: Hemostasis, and thrombosis: basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW (Eds), JB Lippincott Company, Philadelphia, USA (1994):1151–1163.
  • HASS WK, EASTON JD, ADAMS HP et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl. I Med. (1989) 321:501–507.
  • GORELICK PB, RICHARDSON D, KELLY M et al.: Aspirin and ticlopidine for prevention of recurrent stroke in black patients. JAMA (2003) 289:2947–2957.
  • CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
  • BENNETT CL, CONNORS JM, CARWILE JM, MOAKE JL, BELL WR: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl. I Med. (2000) 342:1773–1777.
  • DE GAETANO G, CERLETTI C, BERTELE V: Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet (1982) 2:974–977.
  • ESPS GROUP: European Stroke Prevention Study. Stroke (1990) 21:1122–1130.
  • BOUSSER MG, ESCHWEGE E, HAGUENAU M et al.: AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke (1983) 14:5–14.
  • AMERICAN-CANADIAN CO-OPERATIVE STUDY GROUP: Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke (1985) 16:406–415.
  • MATIAS-GUIU J, DAVALOS A, PICO M, MONASTERIO J, VILASECA J, CODINA A: Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand. (1987) 76:413–421.
  • DIENER HC, CUNHA L, FORBES C, SIVENIUS J, SMETS P, LOWENTHAL A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Neurol Sci. (1996) 143:1–13.
  • MAJOR ONGOING STROKE TRIALS: Stroke (2001) 32:2448–2457.
  • SARASIN FP, GASPOZ JM, BOUNAMEAUX H: Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack [comment]. Arch. Intern. Med. (2000) 160:2773–2778.
  • SHAH H, GONDEK K: Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin. Ther. (2000) 22:362-370; Discussion: 360–361.
  • CHAMBERS M, HUTTON J, GLADMAN J: Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics (1999) 16:577-593 [Erratum published in (2000) 17(1):69].
  • SCHLEINITZ M: Cost effectiveness of antiplatelet therapies. Arch. Intern. Med. (2001) 161:1236.
  • HEIDEBRINK J: Is treatment with aspirin combined with dipyrdiamole really more cost effective than aspirin alone? Arch. Intern. Med. (2001) 161:1236.
  • JOHNSON E, LANES S, WENTWORTH C, SATTERFIELD M, ABEBE B, DICKER L: A metaregression analysis of the dose response effect of aspirin. Arch. Intern. Med. (1999) 159:1248–1253.
  • CORDELL WH: Number needed to treat(NNT). Ann. Enterg. Med. (1999) 33:433–436.

Website

  • http://cp.gsm.com/ Clinical Pharmacology [online database]: Gold Standard Multimedia.
  • http://home.wxs.n1/- esprit/ European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT). Accessed October 2003.
  • http://www.strokecenter.org The Internet Stroke Center. Accessed September 2003.
  • http://www.clinicaltrials.gov Clinical Trials. Accessed September 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.